Clinical Trial Update: A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating telavancin for Staphylococcus aureus bacteremia was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Staphylococcus Aureus Bacteremia

Drugs mentioned

• Telavancin (telavancin)

Snippet

Sponsor: Cumberland Pharmaceuticals | Conditions: Bacteremia | Phase 3 | Status: TERMINATED | Results posted: 2020-02-17